Loading stock data…
$1.77-0.11 (-5.85%)
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer.
Elicio Therapeutics, Inc. in the Healthcare sector is trading at $1.77 with a market capitalization of $48M. Wall Street consensus targets $13.67 (3 analysts), implying a +672.1% move over the next 12 months. The stock is currently near its 52-week low of $1.71, remaining 75.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$10.43M↑ | -$10.60M↓ | -$8.84M↓ | -$8.04M↑ | -$9.68M |
| Net Income | -$8.22M↑ | -$11.82M↓ | -$7.72M↑ | -$10.08M↑ | -$10.56M |
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II cl...